Literature DB >> 24762278

Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.

G Castaman1, A Hillarp, A Goodeve.   

Abstract

The deficiency or abnormal function of von Willebrand factor (VWF) causes von Willebrand disease (VWD), the most frequent inherited bleeding disorder. The laboratory diagnosis of VWD can be difficult as the disease is heterogeneous and an array of assays is required to describe the phenotype. Basic classification of quantitative (type 1 and 3) and qualitative (type 2) VWD variants requires determination of VWF antigenic (VWF:Ag) levels and assaying of VWF ristocetin cofactor (VWF:RCo) activity, determining the capacity of VWF to interact with the platelet GPIb-receptor. Knowing the VWF:RCo activity is essential for identifying, subtyping and monitoring VWD, but the assay is poorly standardized and many protocols do not fulfil the clinical need in all situations. This has led to the development of novel activity assays, independent of ristocetin, with enhanced assay characteristics. Results from the first independent clinical evaluations are promising, showing that they are reliable and suitable for VWD diagnosis. The qualitative type 2 VWF deficiency can be further divided into four different subtypes (A, B, M and N) using specific assays that explore other activities or the size distribution of VWF multimers. These methods are discussed herein. However, in a number of patients it may be difficult to correctly classify the VWD phenotype and genetic analysis may provide the best option to clarify the disorder, through mutation identification.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  genetic testing; laboratory diagnosis; ristocetin cofactor; von Willebrand disease; von Willebrand factor activity

Mesh:

Substances:

Year:  2014        PMID: 24762278      PMCID: PMC4273086          DOI: 10.1111/hae.12410

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  26 in total

1.  A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).

Authors:  A Tosetto; F Rodeghiero; G Castaman; A Goodeve; A B Federici; J Batlle; D Meyer; E Fressinaud; C Mazurier; J Goudemand; J Eikenboom; R Schneppenheim; U Budde; J Ingerslev; Z Vorlova; D Habart; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.

Authors:  F Rodeghiero; G Castaman; A Tosetto; J Batlle; F Baudo; A Cappelletti; P Casana; N De Bosch; J C J Eikenboom; A B Federici; S Lethagen; S Linari; A Srivastava
Journal:  J Thromb Haemost       Date:  2005-12       Impact factor: 5.824

3.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

Authors:  Anne Goodeve; Jeroen Eikenboom; Giancarlo Castaman; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Reinhard Schneppenheim; Ulrich Budde; Jorgen Ingerslev; David Habart; Zdena Vorlova; Lars Holmberg; Stefan Lethagen; John Pasi; Frank Hill; Mohammad Hashemi Soteh; Luciano Baronciani; Christer Hallden; Andrea Guilliatt; Will Lester; Ian Peake
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

4.  Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source.

Authors:  E J Favaloro
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

Review 5.  The utility of the PFA-100 in the identification of von Willebrand disease: a concise review.

Authors:  Emmanuel J Favaloro
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

6.  Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation.

Authors:  Steve Kitchen; Ion Jennings; Tim A L Woods; Dianne P Kitchen; Isobel D Walker; Francis E Preston
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

7.  An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation.

Authors:  Piet Meijer; Frits Haverkate
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

8.  Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.

Authors:  Emmanuel J Favaloro; Roslyn Bonar; Katherine Marsden
Journal:  Clin Lab Sci       Date:  2008

9.  Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor.

Authors:  Anne F Riddell; Keith Gomez; Carolyn M Millar; Gillian Mellars; Saher Gill; Simon A Brown; Megan Sutherland; Mike A Laffan; Thomas A J McKinnon
Journal:  Blood       Date:  2009-08-17       Impact factor: 22.113

10.  Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach.

Authors:  Alberto Tosetto; Giancarlo Castaman; Francesco Rodeghiero
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

View more
  11 in total

1.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

2.  Establishment of an International Reference Reagent for standardization of von Willebrand factor binding to recombinant glycoprotein Ib (VWF:GPIbM and VWF:GPIbR): Official Communication of the SSC.

Authors:  Anthony R Hubbard; Sandra L Haberichter
Journal:  J Thromb Haemost       Date:  2019-05-17       Impact factor: 5.824

Review 3.  Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.

Authors:  I Bodó; J Eikenboom; R Montgomery; J Patzke; R Schneppenheim; J Di Paola
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

4.  Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers.

Authors:  Attila Szederjesi; Luciano Baronciani; Ulrich Budde; Giancarlo Castaman; Paola Colpani; Andrew S Lawrie; Yuan Liu; Robert Montgomery; Flora Peyvandi; Reinhard Schneppenheim; Jürgen Patzke; Imre Bodó
Journal:  J Thromb Haemost       Date:  2020-08-27       Impact factor: 5.824

5.  An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

Authors:  A Szederjesi; L Baronciani; U Budde; G Castaman; A S Lawrie; Y Liu; R Montgomery; F Peyvandi; R Schneppenheim; A Várkonyi; J Patzke; I Bodó
Journal:  J Thromb Haemost       Date:  2018-06-13       Impact factor: 5.824

6.  Effects of Dextran-70 and Albumin on Coagulation in Experimental Hemorrhage in the Guinea Pig.

Authors:  Ulf Schött; Thomas Kander; Peter Bentzer
Journal:  Shock       Date:  2018-09       Impact factor: 3.454

7.  Comparison of Effects of Anti-thrombin Aptamers HD1 and HD22 on Aggregation of Human Platelets, Thrombin Generation, Fibrin Formation, and Thrombus Formation Under Flow Conditions.

Authors:  Katarzyna Derszniak; Kamil Przyborowski; Karolina Matyjaszczyk; Martijn Moorlag; Bas de Laat; Maria Nowakowska; Stefan Chlopicki
Journal:  Front Pharmacol       Date:  2019-02-20       Impact factor: 5.810

8.  Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.

Authors:  Nina Borràs; Javier Batlle; Almudena Pérez-Rodríguez; María Fernanda López-Fernández; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Ignacia Balda; Carme Altisent; Rocío Pérez-Montes; Rosa María Fisac; Gemma Iruín; Sonia Herrero; Inmaculada Soto; Beatriz de Rueda; Víctor Jiménez-Yuste; Nieves Alonso; Dolores Vilariño; Olga Arija; Rosa Campos; María José Paloma; Nuria Bermejo; Rubén Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Lizheidy Sarmiento; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Jesús María César; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Rosa Cornudella; Carlos Aguilar; Francisco Vidal; Irene Corrales
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941

9.  Two cases of von Willebrand disease type 3 in consanguineous Chinese families.

Authors:  Xiong Wang; Ning Tang; Yanjun Lu; Qun Hu; Dengju Li
Journal:  Mol Genet Genomic Med       Date:  2019-12-02       Impact factor: 2.183

10.  Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report.

Authors:  Francesco Rodeghiero; Ingrid Pabinger; Margaret Ragni; Rezan Abdul-Kadir; Erik Berntorp; Victor Blanchette; Imre Bodó; Alessandro Casini; Paolo Gresele; Riitta Lassila; Frank Leebeek; David Lillicrap; Diego Mezzano; Patrizia Noris; Alok Srivastava; Alberto Tosetto; Jerzy Windyga; Barbara Zieger; Mike Makris; Nigel Key
Journal:  Hemasphere       Date:  2019-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.